,i  #aafth ,,congress  #ast ,session    
,h4 ,r4 #ejeg  ,,in ,,the ,,house ,,of  
,,representatives  ,november #ab1       
#bjai,mr4 ,tonko 7for himself and ,mr4  
,mc,kinley7 introduced the following    
bill2 which was referred to the         
,committee on ,energy and ,commerce1 and
 in addition to the ,committee on ,ways 
and ,means1 for a period to be          
subsequently determined by the ,speaker1
 in each case for consideration of such 
provisions as fall within the           
jurisdiction of the committee concerned 
,a ,,bill  ,to clarify the treatment of 
pass-through status under the ,medicare 
outpatient payment system for certain   
drugs4  #a4 ,short title ,this ,act may 
be cited as the ,pass-,through          
,technical ,corrections ,act4  #b4      
,clarification of pass-through status   
under ,medicare ,,opps for certain drugs
 ,notwithstanding section #acja of the  
,consolidated ,appropriations ,act of   
#bjah 7,public ,law #aae-ada71 in the   
case of a radiopharmaceutical drug for  

which pass-through status was provided  
pursuant to section #ahcc7t77#f7 of the 
,social ,security ,act 7#db ,u4,s4,c4   
#aciel7t77#f77 and whose period of      
pass-through status initially expired on
 either ,december #ca1 #bjag1 or        
,december #ca1 #bjah1 if such           
radiopharmaceutical drug is indicated   
for positron emission tomography beta   
amyloid imaging covered under a coverage
 evidence development determination     
under section #ahfb7;a77#a77;,e7 of the 
,social ,security ,act 7#db ,u4,s4,c4   
#aciey7a77#a77;,e771 then such          
pass-through status shall be extended   
until such date that the coverage with  
evidence development review is          
determined by the ,centers for ,medicare
  ,medicaid ,services to be completed4